Literature DB >> 1367399

Studies of serum-free medium for the generation of lymphokine-activated killer cells.

M Togami1, K Yasumoto, T Yano, T Ishida, G Kimura, K Sugimachi, K Nomoto.   

Abstract

We examined a serum-free medium (designated as TYI 101) for the generation of lymphokine-activated killer (LAK) cells from human lymphocytes, regional lymph node lymphocytes (RLNL) and peripheral blood lymphocytes (PBL). TYI 101 medium consisted of, in addition to nutrient mixture, transferrin, insulin, fetuin, sodium selenite, 2-mercaptoethanol, o-phosphorylethanolamine, chick egg yolk and porcine kidney extract. These hormones were effective for supporting RLNL proliferation as assessed by (3H)-thymidine uptake. When human lymphocytes from two different sources were cultivated with recombinant interleukin 2 (rIL-2) in TYI 101 medium, LAK activity was generated. In cultures of PBL from a healthy donor, LAK cells were generated in TYI 101 medium as efficiently as in RPMI 1640 medium supplemented with 10% human AB-type serum (RPMI-AB). In cultures of RLNL from lung cancer patients, LAK activity obtained in TYI 101 medium was about sixty-five percent of that in RPMI-AB. However, the addition of a small amount of AB-type serum improved the generation of LAK activity, LAK cell expansion, and cell viability in TYI 101 medium. We conclude that TYI 101 medium can be used for the generation of LAK cells from human lymph node lymphocytes with supplementation of none or only a reduced amount of human serum.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1367399     DOI: 10.1007/bf00353701

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  16 in total

1.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  K Kato; T Yamada; K Kawahara; H Onda; T Asano; H Sugino; A Kakinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

2.  Cytostatic activity of peripheral blood monocytes against bronchogenic carcinoma cells in patients with lung cancer.

Authors:  E Yanagawa; K Yasumoto; H Manabe; N Nagano; N Hirota; M Ohta; T Hattori; K Nomoto; I Azuma; Y Yamamura
Journal:  Gan       Date:  1979-08

Review 3.  Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality.

Authors:  E A Grimm
Journal:  Biochim Biophys Acta       Date:  1986-12-17

4.  Development of a serum-free medium for growth of NS-1 mouse myeloma cells and its application to the isolation of NS-1 hybridomas.

Authors:  T Kawamoto; J D Sato; A Le; D B McClure; G H Sato
Journal:  Anal Biochem       Date:  1983-04-15       Impact factor: 3.365

5.  Properties of recombinant interleukin 2-cultured tumor-infiltrating lymphocytes in human lung cancer.

Authors:  T Yano; K Yasumoto; M Togami; T Ishida; G Kimura; K Sugimachi; K Nomoto
Journal:  Int J Cancer       Date:  1989-04-15       Impact factor: 7.396

6.  Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy.

Authors:  L M Muul; E P Director; C L Hyatt; S A Rosenberg
Journal:  J Immunol Methods       Date:  1986-04-17       Impact factor: 2.303

7.  A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.

Authors:  R J Melder; T L Whiteside; N L Vujanovic; J C Hiserodt; R B Herberman
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

8.  Serum-free medium for murine and human lymphoid and hybridoma cell lines.

Authors:  M Togami; K Yasuda; M Kariya
Journal:  Cytotechnology       Date:  1991-05       Impact factor: 2.058

9.  Studies of serum-free culture medium in the generation of lymphokine activated killer cells.

Authors:  L M Muul; K Nason-Burchenal; C Hyatt; S Schwarz; D Slavin; E P Director; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-12-24       Impact factor: 2.303

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.